ARROWHEAD PHARMACEUTICALS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$173.37 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-12-31 was -$25.01M.
- ARROWHEAD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-12-31 was -$48.73M.
- ARROWHEAD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-12-31 was -$52.73M, a 155.88% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-12-31 was $94.37M.
- ARROWHEAD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $124.26M.
- ARROWHEAD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$12.40M, a 512.33% decline from fiscal 2023.
- ARROWHEAD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $3.01M.
- ARROWHEAD PHARMACEUTICALS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$76.36M, a 286.53% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$173.37M 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | -$39.13M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$25.01M 10-Q · filed 2026-02-05 | |||
| 2025-09-30 | $124.26M 10-K · filed 2025-11-25 | |||
| 2025-06-30 | $27.48M 10-Q · filed 2026-08-04 | |||
| 2025-03-31 | $83.49M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$48.73M 10-Q · filed 2026-02-05 | |||
| 2024-09-30 | -$12.40M 10-K · filed 2025-11-25 | |||
| 2024-06-30 | -$41.35M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | $16.73M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | -$52.73M 10-Q · filed 2025-02-10 | |||
| 2023-09-30 | $3.01M 10-K · filed 2025-11-25 | |||
| 2023-06-30 | -$2.40M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $27.15M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $94.37M 10-Q · filed 2024-02-06 | |||
| 2022-09-30 | -$76.36M 10-K · filed 2024-11-26 | |||
| 2021-09-30 | $40.94M 10-K · filed 2023-11-29 | |||
| 2020-09-30 | -$78.63M 10-K · filed 2022-11-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |